Previous close | 16.03 |
Open | 16.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 16.40 - 16.40 |
52-week range | 11.96 - 31.74 |
Volume | |
Avg. volume | 39,469 |
Market cap | 14.765B |
Beta (5Y monthly) | 0.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.92 (5.63%) |
Ex-dividend date | 11 May 2023 |
1y target est | N/A |
Royal Philips (NYSE: PHG) is promising a turnaround from its bottom-line woes, which began with one of the largest medical devices recalls in recent history. Two major factors explain the softness in Royal Philips' 2022 results: the ever-expanding recall of its subsidiary Philips Respironics' ventilators and sleep apnea masks, and continuing supply chain problems in the wake of the COVID-19 pandemic. There may be little the Netherlands-based company can do about component shortages, but the high-profile issues it faces due to defective sound abatement (noise reduction) foam in its breathing devices have no clear end.
It's been a good week for Koninklijke Philips N.V. ( AMS:PHIA ) shareholders, because the company has just released its...
Koninklijke Philips ( AMS:PHIA ) Full Year 2022 Results Key Financial Results Revenue: €17.8b (up 3.9% from FY 2021...